(Incorporated in Delaware)

We are developing GyriCalc, our first product, which is a proprietary patented software solution designed to help physicians diagnose autism by identifying early structural markers of neurodevelopmental differences through the automated measurement and analysis of MRI images.. 

We are a medical  device company that uses computerized analysis technology to help clinicians do a better job of diagnosing neurological and neurodevelopmental disorders. 

NeuroSpectrum Insight’s (NSI’s) initial market focus will be the United States and Canada. In the U.S., we filed for marketing clearance with the FDA in early March 2025. We received FDA marketing clearance in July 2025. In Canada, where no regulatory approval is required, we recognize the political nature of the healthcare industry and will prioritize strategic discussions with influential government departments and non-profit organizations to ensure a successful market entry.

Canada operates a publicly funded healthcare system, with the majority of healthcare services — including diagnostic tools — being paid for by provincial governments through their respective health insurance plans. Therefore, while no regulatory approval is required to sell GyriCalc in Canada, reimbursement through provincial healthcare systems is a critical factor in achieving broad market penetration. In order for GyriCalc to be eligible for such coverage, government assessments, submissions to technology evaluation committees, and endorsements by influential non-profit healthcare organizations may be necessary.

Our primary focus is on successfully launching GyriCalc™ for autism and establishing a foothold in the U.S. and Canadian markets.

While GyriCalc currently focuses on autism, NSI envisions expanding its brain analysis software algorithms to support clinicians in diagnosing other neurological conditions, such as dyslexia, ADHD, and schizophrenia. Development plans for these additional markets will be undertaken in the latter half of 2026 after GyriCalc has been established in the autism market. This phased approach underscores our commitment to delivering high-impact solutions that address critical clinical needs without overextending our resources.

Note: NeuroSpectrum has not generated any revenue, according to the prospectus.

Note: Net loss is for the year 2024 and the first half of 2025.